B
Bull
Bull · 25%OCS
$18.72
Scenario price
$7.900
-0.186 (-2.35%)At close
Loading chart…
- High
- 8.070
- Open
- 8.040
- VWAP
- 7.93
- Volume
- 294.73K
- Mkt Cap
- 543.39M
- Low
- 7.820
- Amount
- 2.34M
- EV/EBITDA, TTM
- -1.62
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
AI analysis of Oculis Holding AG (OCS)
HoldOculis Holding AG (OCS) is currently priced at $7.90, significantly below the analyst price target of $39, indicating potential upside. However, the company has a negative forward P/E ratio of 0 and a year-to-date change of -60.50%, which raises concerns about its profitability and market performance. The recent positive FDA feedback on Privosegtor could provide a catalyst for recovery, but the high volatility and significant losses in the past year suggest caution. The main risk is the ongoing negative earnings trend, with a reported loss of $0.20 per share, better than expected but still indicative of financial challenges.
Valuation Metrics
The current forward P/E ratio for Oculis Holding AG (OCS) is 0.00, compared to its 5-year average forward P/E of -5.78.
Alphio AI Price Scenarios for OCS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding OCS
Events Timeline
News
8.510-22NewsfilterPrivosegtor Shows Promise in Treating Optic Neuritis
- 9.010-20Newsfilter
Oculis Unveils New Biomarker Data for Privosegtor at ACTRIMS-ECTRIMS Meeting
- 8.510-19Newsfilter
Oculis Completes Randomization for Licaminlimab Trial in Dry Eye Disease
- 9.008-24Newsfilter
Oculis Initiates PIONEER-1 Trial for Privosegtor in Optic Neuritis
8.508-10GlobenewswireOculis Acquires Privosegtor to Enhance Strategic Flexibility
OCS FAQ — answered by Alphio AI
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide. It operates in the Healthcare sector.
Oculis Holding AG (OCS) is currently priced at $7.90, significantly below the analyst price target of $39, indicating potential upside. However, the company has a negative forward P/E ratio of 0 and a year-to-date change of -60.50%, which raises concerns about its profitability and market performance. The recent positive FDA feedback on Privosegtor could provide a catalyst for recovery, but the high volatility and significant losses in the past year suggest caution. The main risk is the ongoing negative earnings trend, with a reported loss of $0.20 per share, better than expected but still indicative of financial challenges.
Community
More ↗No posts yet
Sign up or log in to join the discussionThis page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.